门诊局部麻醉下尿道周围聚丙烯酰胺水凝胶(Bulkamid)注射:前瞻性单中心系列研究
本研究前瞻性纳入2019年11月至2023年8月单中心92例女性压力性尿失禁患者,在门诊局部麻醉下接受尿道周围Bulkamid注射。术后21%出现并发症,多为Clavien 1级。3个月时USP的SUI与OAB子评分及ICIQ-SF均显著改善(P<.001),术者评估的尿道闭合VAS为最强预测因子。
要点
- 门诊局麻下尿道周围Bulkamid注射在女性压力性尿失禁中可行且耐受性好。
- 92例中22例(21%)出现术后并发症,17例为Clavien 1级,仅1例为Clavien 4级。
- 3个月时USP的SUI与OAB子评分及ICIQ-SF均显著改善(P<.001)。
核心结论
- 门诊局麻下尿道周围Bulkamid注射可行、耐受性好,功能结局与既往报道相似,并发症发生率低且均被良好耐受。
- 作者认为该选择对衰弱患者及寻求微创治疗者可能有重要价值,门诊局麻方案可能特别有意义。
研究设计与样本
- 前瞻性单中心系列研究,2019年11月至2023年8月在单中心门诊收集所有接受局麻下尿道周围Bulkamid注射的女性患者数据。
- 纳入92例女性压力性尿失禁患者,平均年龄78岁(范围30-97岁)。
- 该治疗提供给年龄>80岁和/或合并多种疾病、或拒绝所有其他治疗选择的压力性尿失禁患者。
主要发现
- 92例患者中22例出现术后并发症(21%),其中17例为Clavien 1级并发症,仅1例为Clavien 4级。
- 3个月时泌尿症状谱(USP)的SUI与OAB子评分及ICIQ-SF均显著改善(P<.001)。
- 术者术毕自评的尿道闭合VAS是术后结局最强的预测因子。
临床怎么用
- 作者认为门诊局麻下尿道周围Bulkamid注射对衰弱患者及寻求微创治疗者可能有重要价值。
- 作者认为采用简化局麻方案的门诊环境可能特别有意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report our experience of outpatient periurethral injections of Bulkamid under local anesthesia in the office in female patients for stress urinary incontinence (SUI). Polyacrylamide hydrogel (Bulkamid) is a relatively recent bulking agent which may have a better safety profile than previous generations. METHODS: The data of all women who underwent outpatient periurethral Bulkamid injections under local anesthesia in the office at a single academic center were collected prospectively between November 2019 and August 2023. This therapeutic option was offered to patients who had SUI if >80 years old and/or had multiple comorbidities or if they declined all other therapeutic options. RESULTS: Ninety-two patients were included. The mean age was 78 years (30-97). Twenty-two patients experienced postoperative complications (21%), 17 were Clavien 1 complication, only 1 complication was Clavien= 4. The urinary symptoms profile (USP) SUI and overactive bladder symptom (OAB) subscores and the ICIQ-SF were all significantly improved at 3 months (P <.001). The VAS for urethral coaptation self-assessed by the surgeon at the end of the procedure was the strongest predictor of postoperative outcomes. Periurethral Bulkamid injections are feasible in an outpatient setting in the office using a simplified local anesthesia protocol with great tolerance and with similar functional outcomes than previously reported. The injections have a low rate of complications and every complication has been well tolerated. CONCLUSION: These options may be of great value in frail patients and those looking for a minimally invasive treatment. The local anesthesia protocol with the office setting may be of particular interest.
引用
- Faurie B, Hascoet J, Richard C, et al. Outpatient Periurethral Injections of Polyacrylamide Hydrogel (Bulkamid) Under Local Anesthesia in the Office: A Prospective Single-center Series. Urology. 2024. PMID: 39580117. doi:10.1016/j.urology.2024.11.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。